Table 1 Patient and tumor characteristics
Characteristics | No. of patients (%) | |
|---|---|---|
Age (years) | Median (Range) | 60 (39–79) |
≤ 60 | 43 (52) | |
> 60 | 39 (48) | |
Gender | Male | 60 (73) |
Female | 22 (27) | |
Etiology | Hepatitis B virus | 55 (67) |
Hepatitis C virus | 7 ( 9) | |
Others | 20 (24) | |
Diagnosis history at SBRT | Initially diagnosed | 28 (34) |
Diagnose as recurrence | 54 (66) | |
No. of previous TACE sessions | ≤ 2 | 44 (54) |
> 2 | 38 (46) | |
Alpha-fetoprotein (IU/ml) | Median (Range) | 14.0 (1.3–6055) |
≤ 200 | 60 (73) | |
> 200 | 22 (27) | |
Child-Turcotte-Pugh score | A5 | 61 (74) |
A6 | 13 (16) | |
B7 | 8 (10) | |
Portal vein tumor thrombosis | Yes | 8 (10) |
No | 74 (90) | |
No. of tumor | 1 | 71 (87) |
2* | 9 (11) | |
3* | 2 (2) | |
AJCC stage | T1 | 44 (54) |
T2 | 16 (19) | |
T3 | 22 (27) | |
BCLC stage | A | 43 (53) |
B | 24 (29) | |
C | 15 (18) | |
Okuda stage | I | 64 (78) |
II | 18 (22) | |
CLIP score | 0 | 39 (48) |
1 | 32 (39) | |
2 | 11 (13) | |
Longest diameter (cm) | Median (Range) | 3.0 (1.0–7.0) |
1.0-2.0 | 10 (12) | |
2.1-3.0 | 23 (28) | |
3.1-4.0 | 22 (27) | |
4.1-5.0 | 13 (16) | |
5.1-6.0 | 4 (5) | |
6.1-7.0 | 10 (12) | |
SBRT dose (Gy) | Median (Range) | 51 (33–60) |
< 45 | 32 (39) | |
45–54 | 40 (49) | |
| Â | > 54 | 10 (12) |